CoChat

AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma

Open access
Belforte, Nicolas, Agostinone, Jessica, Alarcon-Martinez, Luis, Villafranca-Baughman, Deborah, Dotigny, Florence, Cueva Vargas, Jorge L., Di Polo, Adriana · 2021 · Molecular Neurodegeneration

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 27 of the 44 sources its claims cite were checked for support.

Abstract

Background: The maintenance of complex dendritic arbors and synaptic transmission are processes that require a substantial amount of energy. Bioenergetic decline is a prominent feature of chronic neurodegenerative diseases, yet the signaling mechanisms that link energy stress with neuronal dysfunction are poorly understood. Recent work has implicated energy deficits in glaucoma, and retinal ganglion cell (RGC) dendritic pathology and synapse disassembly are key features of ocular hypertension damage. Results: We show that adenosine monophosphate-activated protein kinase (AMPK), a conserved energy biosensor, is strongly activated in RGC from mice with ocular hypertension and patients with primary open angle glaucoma. Our data demonstrate that AMPK triggers RGC dendrite retraction and synapse elimination. We show that the harmful effect of AMPK is exerted through inhibition of the mammalian target of rapamycin complex 1 (mTORC1). Attenuation of AMPK activity restores mTORC1 function and rescues dendrites and synaptic contacts. Strikingly, AMPK depletion promotes recovery of light-evoked retinal responses, improves axonal transport, and extends RGC survival. Conclusions: This study identifies AMPK as a critical nexus between bioenergetic decline and RGC dysfunction during pressure-induced stress, and highlights the importance of targeting energy homeostasis in glaucoma and other neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

AMPK is hyperactivated in retinal ganglion cells (RGCs) after ocular hypertension in mice and in primary open-angle glaucoma patient retinas, and this activation drives dendrite retraction and synapse loss. Attenuating AMPK restores mTORC1 signaling, rescues dendrites and synapses, improves light-evoked retinal responses and axonal transport, and extends RGC survival.

Key findings

  • At 2 weeks after microbead-induced ocular hypertension, RGC dendritic area, length, and branch number decreased by 22%, 28%, and 24%, respectively, and pre-/postsynaptic VGLUT1–PSD95 colocalized voxels in the inner plexiform layer decreased by 65%.
  • Active AMPK (pAMPKThr172) increased in RGCs from ocular hypertensive mice as early as 1 week and was also elevated in RGCs from primary open-angle glaucoma patients, with a reported two-fold increase in pAMPKThr172-positive RGC epifluorescence versus age-matched controls.
  • AMPK knockdown with siAMPK protected dendritic field area (90%), length (86%), and branches (93%) versus siCTL (area 62%, length 66%, branches 80%), and rescued VGLUT1/PSD95 synaptic voxels; co-administration of rapamycin blocked these dendritic and synaptic rescues.
  • siAMPK improved RGC function and survival: pSTR amplitude was preserved, anterograde CTB transport was 93% versus 62% in controls, RGC soma survival was 93% versus 75%, and optic nerve axon survival was 98% versus 78%.

Methods

  • Unilateral ocular hypertension was induced in female Thy1-YFPH or wild-type littermate mice (3–4 months old) by magnetic microbead injection into the anterior chamber; intraocular pressure was measured biweekly, and sham controls received PBS.
  • Human retinas were obtained from 27 primary open-angle glaucoma surgical specimens and 15 age-matched controls; RGCs were identified with Brn3a or RBPMS and analyzed for pAMPKThr172 by immunohistochemistry.
  • Interventions included intraperitoneal compound C or rapamycin and intravitreal siAMPK or control siRNA; outcomes included dendritic arbor reconstruction, synaptic marker voxel analysis, western blot, qPCR, ERG pSTR, CTB axonal transport, and RGC soma/axon counts, analyzed by ANOVA with Tukey’s post hoc test or Student’s t-test.

Limitations

  • The paper states that complete AMPK inhibition can be detrimental, that the siRNA approach conferred only partial AMPK inhibition, and that the timing and duration of AMPK modulation are critical; it also notes that rapamycin can have non-specific or off-target effects and that a narrow 2-week therapeutic window was used.
  • Evident from the text: the mechanistic evidence comes mainly from a mouse microbead ocular hypertension model, with human data limited to postmortem/surgical POAG specimens and no direct human intervention; mouse experiments used female mice only.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13024-021-00466-z

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Ocular hypertension promotes early RGC dendrite retraction and synapse loss. A Schematic of magnetic microbeads injection into the mouse anterior chamber to induce ocular hypertension (OHT). B This procedure results in gradual increase of intraocular pressure (IOP) leading to RGC soma and axon loss (ANOVA with Tukey’s multiple comparison post-hoc test, ***p < 0.001, N = 10–14 mice/group). C, D Quantitative analysis demonstrates a statistically significant loss of RGC soma and axons at 3 weeks after microbeads injection (ANOVA with Tukey’s multiple comparison post-hoc test, n.s. = not significant, ***p < 0.001, N = 5–14 mice per group). (E) YFP-positive RGC with a clearly identifiable axon (arrowhead) were selected for dendritic arbor imaging and 3D reconstruction. F, G Representative examples of RGC dendritic arbors from non-injured (sham) and glaucomatous retinas at 2 weeks after induction of OHT. H-K Quantitative analysis of dendritic parameters reveals a substantial reduction in dendritic area, length, number of branches, and complexity (Sholl analysis) in OHT retinas (blue) relative to sham controls (white) (Student’s t-test, **p < 0.01, ***p < 0.001, N = 6 mice/group, n = 40–51 RGC/group Table 1). L-N Glutamatergic synapses are visualized in the inner plexiform layer (IPL) on retinal cross-sections using immunolabeling against PSD95 (green) and VGLUT1 (red), post- and pre-synaptic markers, respectively. OHT injury (2 weeks) induces a pronounced loss of both VGLUT1 and PSD95 expression in the IPL. O High magnification of inset in (N) shows VGLUT1 and PSD95 puncta in the IPL at the level of the OFF sublamina in OHT and sham retinas. P Quantitative analysis of pre- and postsynaptic co-localized voxels, which measured the three-dimensional volume occupied by both VGLUT1 and PSD95 in the IPL, confirms that OHT promotes a striking loss of synapses (Student’s t-test, ***p < 0.001, N = 4 mice/group). Values are expressed as the mean ± S.E.M
Fig. 1 Ocular hypertension promotes early RGC dendrite retraction and synapse loss. A Schematic of magnetic microbeads injection into the mouse anterior chamber to induce ocular hypertension (OHT). B This procedure results in gradual increase of intraocular pressure (IOP) leading to RGC soma and axon loss (ANOVA with Tukey’s multiple comparison post-hoc test, ***p < 0.001, N = 10–14 mice/group). C, D Quantitative analysis demonstrates a statistically significant loss of RGC soma and axons at 3 weeks after microbeads injection (ANOVA with Tukey’s multiple comparison post-hoc test, n.s. = not significant, ***p < 0.001, N = 5–14 mice per group). (E) YFP-positive RGC with a clearly identifiable axon (arrowhead) were selected for dendritic arbor imaging and 3D reconstruction. F, G Representative examples of RGC dendritic arbors from non-injured (sham) and glaucomatous retinas at 2 weeks after induction of OHT. H-K Quantitative analysis of dendritic parameters reveals a substantial reduction in dendritic area, length, number of branches, and complexity (Sholl analysis) in OHT retinas (blue) relative to sham controls (white) (Student’s t-test, **p < 0.01, ***p < 0.001, N = 6 mice/group, n = 40–51 RGC/group Table 1). L-N Glutamatergic synapses are visualized in the inner plexiform layer (IPL) on retinal cross-sections using immunolabeling against PSD95 (green) and VGLUT1 (red), post- and pre-synaptic markers, respectively. OHT injury (2 weeks) induces a pronounced loss of both VGLUT1 and PSD95 expression in the IPL. O High magnification of inset in (N) shows VGLUT1 and PSD95 puncta in the IPL at the level of the OFF sublamina in OHT and sham retinas. P Quantitative analysis of pre- and postsynaptic co-localized voxels, which measured the three-dimensional volume occupied by both VGLUT1 and PSD95 in the IPL, confirms that OHT promotes a striking loss of synapses (Student’s t-test, ***p < 0.001, N = 4 mice/group). Values are expressed as the mean ± S.E.MCC BY · PubMed Central
Fig. 2 Glaucoma-induced energy stress triggers AMPK activation. A, B Western blot and densitometry analysis of retinal homogenates demonstrate a substantial increase in active AMPK (pAMPKThr172), a readout of metabolic stress, as early as 1 week after induction of OHT (Student’s t-test, * = p<0.05, N = 5 mice/group). The lower panel is the same blot probed with an antibody against total AMPK and β-actin for normalization. C, D Western blot and densitometry analysis of retinal homogenates show increased LKB1 activity (pLKB1) in glaucomatous retinas (Student’s t-test, ** = p<0.01, N = 7–9 mice/group). The lower panel is the same blot probed with an antibody against total LKB1 and β-actin for normalization. E, F Immunohistochemical analysis of mouse retinal cross sections with an antibody against pAMPKThr172, reveals robust AMPK activity in retinal cells subjected to OHT. G, H Co-labeling with antibodies against pAMPKThr172 and the RGC-specific marker Brn3a demonstrates AMPK hyperactivity in RGC. I, J Quantification of the number of pAMPKThr172-positive RGC as well as epifluorescence intensity per neuron confirms a significant increase in AMPK activity (Student’s t-test, ** = p<0.01, N = 5 mice/group, n = 50 RGC/group). K, L pAMPKThr172 retinal immunostaining of primary open angle glaucoma patients and age-matched controls (Table 2) reveals increased AMPK function. M, N Co-labeling with anti-pAMPKThr172 and RBPMS, a selective marker for RGC, confirms AMPK overactivation in glaucomatous RGC. O Quantification of epifluorescence intensity in pAMPKThr172-positive RGC demonstrates a two-fold increase in AMPK activity in human glaucomatous retinas relative to age-matched controls (Student’s t-test, ** = p<0.01, glaucoma: N = 27 retinas/group, n = 100 RGC/group; controls: N = 15 retinas/group, n = 100 RGC/group). P Administration of compound C (CC), an inhibitor of AMPK, results a significant decrease in AMPK activity compared to vehicle-treated eyes. (Student’s t-test, *** = p<0.001, N = 5 mice/group). Q, R Representative examples of dendritic arbors from OHT retinas treated with vehicle or CC, an inhibitor of AMPK, visualized at 2 weeks after microbeads injection. S-V Quantitative analysis of dendritic parameters reveals that CC-treated neurons had longer dendrites and markedly larger and more complex arbors than vehicle-treated controls (CC: green, vehicle: grey, sham controls: white) (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, *** = p<0.001, N = 4–6 mice/group, n = 30–40 RGC/group, Table 3). W, X Brn3a-labeled flat-mounted retinas display greater RGC soma density at 3 weeks of OHT following CC administration compared to vehicle (ANOVA with Tukey’s multiple comparison post-hoc test, ** = p<0.01, N = 5–8 mice/group). Values are expressed as the mean ± S.E.M. ONL: Outer Nuclear Layer, OPL: Outer Plexiform Layer, INL: Inner Nuclear Layer, IPL: Inner Plexiform Layer, GCL: Ganglion Cell Layer
Fig. 2 Glaucoma-induced energy stress triggers AMPK activation. A, B Western blot and densitometry analysis of retinal homogenates demonstrate a substantial increase in active AMPK (pAMPKThr172), a readout of metabolic stress, as early as 1 week after induction of OHT (Student’s t-test, * = p<0.05, N = 5 mice/group). The lower panel is the same blot probed with an antibody against total AMPK and β-actin for normalization. C, D Western blot and densitometry analysis of retinal homogenates show increased LKB1 activity (pLKB1) in glaucomatous retinas (Student’s t-test, ** = p<0.01, N = 7–9 mice/group). The lower panel is the same blot probed with an antibody against total LKB1 and β-actin for normalization. E, F Immunohistochemical analysis of mouse retinal cross sections with an antibody against pAMPKThr172, reveals robust AMPK activity in retinal cells subjected to OHT. G, H Co-labeling with antibodies against pAMPKThr172 and the RGC-specific marker Brn3a demonstrates AMPK hyperactivity in RGC. I, J Quantification of the number of pAMPKThr172-positive RGC as well as epifluorescence intensity per neuron confirms a significant increase in AMPK activity (Student’s t-test, ** = p<0.01, N = 5 mice/group, n = 50 RGC/group). K, L pAMPKThr172 retinal immunostaining of primary open angle glaucoma patients and age-matched controls (Table 2) reveals increased AMPK function. M, N Co-labeling with anti-pAMPKThr172 and RBPMS, a selective marker for RGC, confirms AMPK overactivation in glaucomatous RGC. O Quantification of epifluorescence intensity in pAMPKThr172-positive RGC demonstrates a two-fold increase in AMPK activity in human glaucomatous retinas relative to age-matched controls (Student’s t-test, ** = p<0.01, glaucoma: N = 27 retinas/group, n = 100 RGC/group; controls: N = 15 retinas/group, n = 100 RGC/group). P Administration of compound C (CC), an inhibitor of AMPK, results a significant decrease in AMPK activity compared to vehicle-treated eyes. (Student’s t-test, *** = p<0.001, N = 5 mice/group). Q, R Representative examples of dendritic arbors from OHT retinas treated with vehicle or CC, an inhibitor of AMPK, visualized at 2 weeks after microbeads injection. S-V Quantitative analysis of dendritic parameters reveals that CC-treated neurons had longer dendrites and markedly larger and more complex arbors than vehicle-treated controls (CC: green, vehicle: grey, sham controls: white) (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, *** = p<0.001, N = 4–6 mice/group, n = 30–40 RGC/group, Table 3). W, X Brn3a-labeled flat-mounted retinas display greater RGC soma density at 3 weeks of OHT following CC administration compared to vehicle (ANOVA with Tukey’s multiple comparison post-hoc test, ** = p<0.01, N = 5–8 mice/group). Values are expressed as the mean ± S.E.M. ONL: Outer Nuclear Layer, OPL: Outer Plexiform Layer, INL: Inner Nuclear Layer, IPL: Inner Plexiform Layer, GCL: Ganglion Cell LayerCC BY · PubMed Central
Fig. 3 AMPK hyperactivation promotes dendritic retraction and synapse loss in glaucoma. A-C Western blot and densitometry analysis confirm that intravitreal delivery of siAMPK reduced retinal AMPK protein and its function, visualized with an antibody against pAMPKThr172 (active form) (Student’s t-test, * = p < 0.05, N = 4 mice/group). The lower panel is the same blot as in the upper panels but probed with an antibody that recognizes β-actin to ensure equal protein loading. D siAMPK or its control siRNA (siCTL) are administered by intravitreal injection once a week, starting at 3 days after glaucoma induction. RGC dendritic and synaptic analyses are carried out at 2 weeks after injury. E, F siAMPK administration results in marked reduction of AMPK activity in RGC, visualized by co-labeling with pAMPKThr172 and Brn3a on retinal cross sections. G Quantification of pAMPKThr172- and Brn3a-positive cells confirms a significant decrease of AMPK function in glaucomatous eyes treated with siAMPK (Student’s t-test, **p < 0.01, N = 5 mice/group, n = 50 RGC/group). H, I siAMPK-treated RGC have longer dendrites and more elaborate arbors than control neurons treated with siCTL. J-M Quantitative analysis of dendritic parameters and Sholl analysis confirm that siAMPK-mediated AMPK knockdown significantly increased the area, length, number of branches and complexity of RGC dendrites (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, ** = p < 0.01, * = p<0.05, N = 5 mice/group, n = 30–50 RGC/group, Table 1). (N-Q) siAMPK also rescues VGLUT1 and PSD95 expression in RGC dendrites, and quantitative analysis of pre- and postsynaptic voxels confirms robust synaptic protection compared to controls (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, N = 5 mice/group). Values are expressed as the mean ± S.E.M. INL: Inner Nuclear Layer, IPL: Inner Plexiform Layer, GCL: Ganglion Cell Layer
Fig. 3 AMPK hyperactivation promotes dendritic retraction and synapse loss in glaucoma. A-C Western blot and densitometry analysis confirm that intravitreal delivery of siAMPK reduced retinal AMPK protein and its function, visualized with an antibody against pAMPKThr172 (active form) (Student’s t-test, * = p < 0.05, N = 4 mice/group). The lower panel is the same blot as in the upper panels but probed with an antibody that recognizes β-actin to ensure equal protein loading. D siAMPK or its control siRNA (siCTL) are administered by intravitreal injection once a week, starting at 3 days after glaucoma induction. RGC dendritic and synaptic analyses are carried out at 2 weeks after injury. E, F siAMPK administration results in marked reduction of AMPK activity in RGC, visualized by co-labeling with pAMPKThr172 and Brn3a on retinal cross sections. G Quantification of pAMPKThr172- and Brn3a-positive cells confirms a significant decrease of AMPK function in glaucomatous eyes treated with siAMPK (Student’s t-test, **p < 0.01, N = 5 mice/group, n = 50 RGC/group). H, I siAMPK-treated RGC have longer dendrites and more elaborate arbors than control neurons treated with siCTL. J-M Quantitative analysis of dendritic parameters and Sholl analysis confirm that siAMPK-mediated AMPK knockdown significantly increased the area, length, number of branches and complexity of RGC dendrites (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, ** = p < 0.01, * = p<0.05, N = 5 mice/group, n = 30–50 RGC/group, Table 1). (N-Q) siAMPK also rescues VGLUT1 and PSD95 expression in RGC dendrites, and quantitative analysis of pre- and postsynaptic voxels confirms robust synaptic protection compared to controls (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, N = 5 mice/group). Values are expressed as the mean ± S.E.M. INL: Inner Nuclear Layer, IPL: Inner Plexiform Layer, GCL: Ganglion Cell LayerCC BY · PubMed Central
Fig. 4 AMPK knockdown rescues RGC dendrites and synapses through mTORC1 activation. A Immunolabeling of non-injured sham retinas with pS6Ser240/244 reveals two cell populations endowed with robust constitutively active mTORC1: one located in the ganglion cell layer and another in the inner nuclear layer. B Co-labeling with antibodies against pS6Ser240/244 and RBPMS show robust mTORC1 activity in these neurons. C-E OHT markedly reduces pS6Ser240/244 labeling in RGC, indicating loss of mTORC1 function. F-H Administration of siAMPK in glaucomatous retinas restores mTORC1 activity in RGC relative to controls (Student’s t-test, ** = p<0.01, N = 5 mice/group). I, J Co-administration of siAMPK and rapamycin (Rap), an inhibitor of mTORC1, blocks the effect of siAMPK on dendritic rescue. K-N Quantification of dendritic parameters confirms a substantial reduction in area, process length, number of branches, and complexity (Sholl analysis) in rapamycin-treated retinas compared to vehicle-treated controls (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, ** = p < 0.01, * = p<0.05, N = 4 mice/group, n = 30–50 RGC/group, Table 1). O, P Rapamycin also blocks siAMPK-mediated rescue of synapses, visualized with the post- and pre-synaptic markers PSD95 and VGLUT1, respectively. Q Quantification of synaptic voxels confirms that siAMPK-induced synaptic protection is abolished by rapamycin, confirming that this process is mTORC1 dependent (Student’s t-test, ***p < 0,001, N = 5 mice/group). Values are expressed as the mean ± S.E.M. IPL: Inner Plexiform Layer, GCL: Ganglion Cell Layer
Fig. 4 AMPK knockdown rescues RGC dendrites and synapses through mTORC1 activation. A Immunolabeling of non-injured sham retinas with pS6Ser240/244 reveals two cell populations endowed with robust constitutively active mTORC1: one located in the ganglion cell layer and another in the inner nuclear layer. B Co-labeling with antibodies against pS6Ser240/244 and RBPMS show robust mTORC1 activity in these neurons. C-E OHT markedly reduces pS6Ser240/244 labeling in RGC, indicating loss of mTORC1 function. F-H Administration of siAMPK in glaucomatous retinas restores mTORC1 activity in RGC relative to controls (Student’s t-test, ** = p<0.01, N = 5 mice/group). I, J Co-administration of siAMPK and rapamycin (Rap), an inhibitor of mTORC1, blocks the effect of siAMPK on dendritic rescue. K-N Quantification of dendritic parameters confirms a substantial reduction in area, process length, number of branches, and complexity (Sholl analysis) in rapamycin-treated retinas compared to vehicle-treated controls (ANOVA with Tukey’s multiple comparison post-hoc test, *** = p<0.001, ** = p < 0.01, * = p<0.05, N = 4 mice/group, n = 30–50 RGC/group, Table 1). O, P Rapamycin also blocks siAMPK-mediated rescue of synapses, visualized with the post- and pre-synaptic markers PSD95 and VGLUT1, respectively. Q Quantification of synaptic voxels confirms that siAMPK-induced synaptic protection is abolished by rapamycin, confirming that this process is mTORC1 dependent (Student’s t-test, ***p < 0,001, N = 5 mice/group). Values are expressed as the mean ± S.E.M. IPL: Inner Plexiform Layer, GCL: Ganglion Cell LayerCC BY · PubMed Central
Fig. 5 AMPK attenuation promotes RGC functional recovery and survival. A-C Representative positive scotopic threshold response (pSTR) recordings prior to induction of ocular hypertension (pre-OHT, yellow trace) or after injury and treatment with siCTL (grey trace) or siAMPK (red trace). Pre- and post-OHT recordings are normalized relative to the contralateral, non-injured eye (black traces). D Quantitative analysis of the pSTR amplitude demonstrates RGC function rescue in siAMPK-treated eyes relative to controls at 3 weeks after OHT induction (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 8–18 mice/group). E The tracer cholera toxin B subunit (CTB) conjugated to Alexa Fluor 488 is injected intravitreally and its accumulation in the contralateral superior colliculus is quantified as a readout of active anterograde axonal transport. F-H Unbiased stereological rostral-to-caudal sampling of the superior colliculi demonstrates a substantial reduction of the CTB-labeled target area in siCTL-treated mice relative to sham controls. In contrast, siAMPK-treated animals display an increase in brain CTB accumulation. I Quantification of the total CTB-positive area in the superior colliculus confirms a marked increase in anterograde axonal transport in siAMPK-treated mice compared to siCTL (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–9 mice/group). J-M Brn3a-labeled flat-mounted retinas show higher RGC soma density at 3 weeks of OHT following siAMPK treatment relative to controls (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–12 mice/group). N-Q siAMPK also promotes survival of RGC axons, quantified in optic nerve cross sections, compared to retinas treated with siCTL (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–6 mice/group). Values are expressed as the mean ± S.E.M
Fig. 5 AMPK attenuation promotes RGC functional recovery and survival. A-C Representative positive scotopic threshold response (pSTR) recordings prior to induction of ocular hypertension (pre-OHT, yellow trace) or after injury and treatment with siCTL (grey trace) or siAMPK (red trace). Pre- and post-OHT recordings are normalized relative to the contralateral, non-injured eye (black traces). D Quantitative analysis of the pSTR amplitude demonstrates RGC function rescue in siAMPK-treated eyes relative to controls at 3 weeks after OHT induction (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 8–18 mice/group). E The tracer cholera toxin B subunit (CTB) conjugated to Alexa Fluor 488 is injected intravitreally and its accumulation in the contralateral superior colliculus is quantified as a readout of active anterograde axonal transport. F-H Unbiased stereological rostral-to-caudal sampling of the superior colliculi demonstrates a substantial reduction of the CTB-labeled target area in siCTL-treated mice relative to sham controls. In contrast, siAMPK-treated animals display an increase in brain CTB accumulation. I Quantification of the total CTB-positive area in the superior colliculus confirms a marked increase in anterograde axonal transport in siAMPK-treated mice compared to siCTL (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–9 mice/group). J-M Brn3a-labeled flat-mounted retinas show higher RGC soma density at 3 weeks of OHT following siAMPK treatment relative to controls (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–12 mice/group). N-Q siAMPK also promotes survival of RGC axons, quantified in optic nerve cross sections, compared to retinas treated with siCTL (ANOVA with Tukey’s multiple comparison post-hoc test, * = p<0.05, N = 5–6 mice/group). Values are expressed as the mean ± S.E.MCC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 1 Not valid · 6 Not checked · 94 Own results and interpretations

77 more claims · 2 with their cited sources checked

Create a free account to see all 121 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 19
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 68 references

Cited by

See all 73

Metadata

Authors
Belforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A.
Affiliations
Centre Hospitalier de l’Université de Montréal (CA)
Venue
Molecular Neurodegeneration
Published
2021-06-29
Volume
16
Issue
1
Pages
43-43
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3174825856
Cited by
67
References
68
Citations by year
2026: 12 · 2025: 18 · 2024: 13 · 2023: 14 · 2022: 10
FWCI
8.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Eye Institute (1R01EY030838-01)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
AMPK, glaucoma, retinal ganglion cells, dendrite retraction, synaptic loss, mTORC1, ocular hypertension, bioenergetic stress, energy homeostasis, axonal transport, neuronal survival, neurodegeneration
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Adenylate Kinase, Animals, Dendrites, Enzyme Activation, Glaucoma, Open-Angle, Humans, Retinal Ganglion Cells, Synapses, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma. https://app.cochat.ai/papers/10.1186/s13024-021-00466-z
The paper
Belforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A. (2021). AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00466-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.